Related Experiment Video
Updated: Feb 14, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Sreekanth Thota1,2, Daniel A Rodrigues2, Debbie C Crans3
1National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Fundação Oswaldo Cruz, Ministério da Saúde, Av. Brazil 4036, Prédio da Expansão, 8° Andar, Sala 814, Manguinhos , 21040-361 Rio de Janeiro , RJ , Brazil.
Ruthenium (Ru) compounds show promise as cancer therapeutics, overcoming resistance to platinum drugs. Research explores their use in diagnostics and treatments, including novel Ru(II) designs and nanomaterial delivery systems.
Area of Science:
- Oncology
- Medicinal Chemistry
- Nanotechnology
Background:
- Metal-based drugs are crucial in oncology, with theranostic agents offering dual diagnostic and therapeutic benefits.
- Ruthenium compounds exhibit selective bioactivity and can overcome resistance common with platinum-based therapeutics.
- Several ruthenium complexes (NAMI-A, KP1019, KP1339) have advanced to clinical trials, with DW1/2 in preclinical development.
Purpose of the Study:
- To highlight the potential of ruthenium (Ru) compounds as next-generation anticancer agents.
- To review strategies for enhancing the delivery and efficacy of Ru-based therapeutics.
- To discuss the application of Ru(II) compounds in photodynamic therapy and as protein kinase inhibitors.
Main Methods:
- Review of existing literature on ruthenium-based oncology research.
- Analysis of specific ruthenium complexes and their mechanisms of action.
- Exploration of nanomaterial encapsulation and photodynamic therapy applications for Ru compounds.
Main Results:
- Ruthenium compounds demonstrate selective anticancer activity and potential to overcome drug resistance.
- Organometallic Ru(II) compounds like DW1/2 function as protein kinase inhibitors.
- Nanomaterial encapsulation improves targeting and delivery of Ru(II) compounds into cancer cells.
- Ru(II)-based compounds are effective photosensitizers for photodynamic therapy (TLD-1433 in clinical trials).
Conclusions:
- Ruthenium compounds represent a valuable class of anticancer agents with diverse therapeutic applications.
- Advanced strategies like nanomaterial delivery and photodynamic therapy enhance the efficacy of ruthenium therapeutics.
- Ruthenium-based drugs offer a promising alternative and complementary approach to conventional cancer treatments.
Related Concept Videos
Molecules and Compounds
Organic Compounds
Elements and Compounds
Elements
Elements are classified as atomic or molecular based on the nature of their basic units. They are unique forms of matter with specific chemical and physical properties that cannot break down into smaller substances by ordinary chemical reactions. There...
Ionic Compounds: Formulas and Nomenclature
Solubility of Ionic Compounds
Classification of Elements and Compounds
Compounds are pure substances composed of two or more elements in fixed, definite proportions. Compounds are classified as ionic or molecular (covalent) based on the bonds...

